Industry Insights

  1. How FDA Alignment Is Shaping Opus Genetics' OPGx-LCA5 Development Strategy 8/12/2026

    Opus Genetics shares how FDA alignment yielded a clearer path for its ultra-rare LCA5 gene therapy, shaping trial design, evidence generation, and operations.

  2. Why Vendor Oversight Breaks Down At Handoffs 8/11/2026

    Is a vendor handoff really complete once the file is sent? Not quite. Sponsors still need context, ownership, and evidence to keep trials moving.

  3. Don't Accept This Site-Level Start-Up Bottleneck— Instead, Learn How To Stop It 8/10/2026

    Combining investigator meetings and SIVs can cut site activation timelines in half — if sponsors build a compliance-sound case and involve QA early.

  4. 7 Practical Implications Of ICH E6(R3) For Early-Phase Trial Design 8/10/2026

    A risk-based quality approach can enhance participant protection, data integrity, and development success through focused oversight, strong governance, and clear documentation.

  5. Enhance Recruitment & Retention For Rare Kidney Disease Trials 8/10/2026

    Though the burdens of developing treatments for rare kidney diseases are high, data-driven recruitment strategies and experienced CRO teams will help ensure accessible trials with strong enrollment.

  6. What It Takes To Validate A Biomarker For Real-World, Post-Transplant Care 8/7/2026

    Yelena Bushman, MBA, VP of cell therapy and transplant at CareDx, discusses the operational challenges of validating biomarkers for post-transplant care.

  7. July Update — U.S. Generic Drug Tariffs: Implications For Pharma And Outsourcing 8/7/2026

    Mathini Ilancheran updates us on how delayed U.S. tariffs on generic drug imports could reshape supply, sourcing, and trial planning.

  8. Traditional, Hybrid Or Decentralized: What Actually Works? 8/6/2026

    Learn how traditional, decentralized, and community-based approaches address different study challenges and support more effective, patient-centered research.

  9.  Life Sciences Meetings Need More Than Logistics 8/6/2026

    Life sciences meetings often extend beyond investigators’ meetings. Strong planning helps teams support clinical, commercial, governance, and internal programs without adding pressure to the host team.

  10. Financial Barriers In Clinical Trials: What Patient Data Tells Us 8/5/2026

    Prospective clinical trial participants rank financial transparency as a decisive factor before enrolling. Discover how removing out-of-pocket friction drives patient recruitment and retention.